GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE4 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Psoriasis flare drug study pulled before it began
Disease control TerminatedThis study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It w…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug TAK-279 targets rare, severe psoriasis in phase 3 trial
Disease control OngoingThis phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-l…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC